BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Constella Group And SAS Offer Turnkey Electronic Drug Development Solution


10/19/2005 5:08:43 PM

WASHINGTON, June 14 /PRNewswire/ -- Constella Group, Inc., the leader in providing evidence-based health intelligence, and SAS, the leader in business intelligence, announced today that the two companies will provide an integrated offering that allows life sciences companies to merge the day-to-day planning and execution of clinical trials with powerful data integration and analysis. The joint offering -- Constella Orion(TM) Powered by SAS(R) Drug Development -- works through an ASP platform to provide U.S.-based customers with direct visibility into the total clinical project through a single, intuitive interface.

The joint offering, available now and debuting at the 40th annual Drug Information Association (DIA) conference in Washington, D.C., provides companies with the ability to actively monitor the progress of clinical trials and proactively take action to address problems -- such as delays in overall patient enrollment -- instead of learning about these issues at a later date from a paper report issued at a pre-determined milestone. Licensed on a per-trial basis to pharmaceutical, biotechnology and medical device firms engaging in Phase II through Phase IV clinical trials, the SAS and Constella offering provides a cost-effective approach to implementing and managing new technologies.

At the same time, customers can analyze the collected clinical trials data for regulatory submission and explore their research for new market opportunities, product line extensions and safety issues, all within a controlled and secure collaborative framework designed for life sciences research industries.

"Together with SAS, we are creating a seamless, end-to-end drug development platform unlike any other on the market," said Donald A. Holzworth, Constella CEO. "This highly affordable platform is designed to increase R&D efficiency, improve collaboration and information exchange among study teams and sponsors, and accelerate time to market with excellent regulatory support and direction."

While electronic clinical technologies are critical to the long-term development strategies of life sciences companies, many cannot afford to invest heavily in such technology. In addition, these technologies traditionally have been highly fragmented, functionally limited and not clearly supportive of government regulations such as 21 CFR Part 11 and the Prescription Drug Users Fee Act.

"With the integration of SAS Drug Development and Constella Orion, customers will not only manage, but truly collaborate around life sciences research programs through a secure, Web-based environment that provides the regulatory support that is required," said Kecia Serwin, general manager of SAS' Health and Life Sciences group. "All authorized users will have real-time access to research data, allowing them to drill down, extract and analyze study data, without the aid of a programmer and without having to change their work environments. This way, customers can readily obtain critical intelligence to make fast and well-informed go/no-go decisions throughout the development process."

About Constella Group

Constella Group ( http://www.constellagroup.com/ ) is a leading provider of professional health services worldwide, dedicated to enhancing human health through innovative science, technology and knowledge solutions. Constella's three business units -- Health Sciences, Clinical Informatics and Health Strategies -- create and provide health intelligence to help industry and government clients identify and address critical issues affecting human health. The company's more than 700 employees serve clients from company headquarters in Durham, N.C., and from offices in Research Triangle Park, N.C., Cambridge, Mass.; Atlanta; Morgantown, W.Va.; Bethesda, Frederick and Silver Spring, Md., and Herndon, Va.

About SAS

SAS is the market leader in providing a new generation of business intelligence software and services that create true enterprise intelligence. SAS solutions are used at more than 40,000 sites -- including 96 of the top 100 companies on the 2003 FORTUNE Global 500(R) -- to develop more profitable relationships with customers and suppliers; to enable better, more accurate and informed decisions; and to drive organizations forward. SAS is the only vendor that completely integrates leading data warehousing, analytics and traditional BI applications to create intelligence from massive amounts of data. For nearly three decades, SAS has been giving customers around the world The Power to Know(R). Visit us at http://www.sas.com/ .

Constella Group, Inc.

CONTACT: Katherine Smart of Constella Group, +1-919-313-7612, orksmart@constellagroup.com; or Bob Chase of SAS, +1-919-531-4327, orBob.Chase@sas.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES